Show simple item record

dc.contributor.authorKoppen, Elias
dc.contributor.authorOmland, Torbjørn
dc.contributor.authorLarsen, Alf Inge
dc.contributor.authorKarlsen, Trine
dc.contributor.authorLinke, Axel
dc.contributor.authorPrescott, Eva Irene Bossano
dc.contributor.authorHalle, Martin
dc.contributor.authorDalen, Håvard
dc.contributor.authorDelagardelle, Charles
dc.contributor.authorHole, Torstein
dc.contributor.authorvan Craenenbroeck, Emeline M.
dc.contributor.authorBeckers, Paul
dc.contributor.authorEllingsen, Øyvind
dc.contributor.authorFeiereisen, Patrick
dc.contributor.authorValborgland, Torstein
dc.contributor.authorVidem, Vibeke
dc.identifier.citationESC Heart Failure. 2021, 8 (3), 2183-2192.en_US
dc.description.abstractPlasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect and isotype Mproteins. Increasing demands to detect low-level disease and new therapeutic monoclonal immunoglobulin treatments have stretched the electrophoretic methods to their analytical limits. Newer techniques based on mass spectrometry (MS) are emerging which have improved clinical and analytical performance. MS is gaining traction into clinical laboratories, and has replaced immunofixation electrophoresis (IFE) in routine practice at one institution. The International Myeloma Working Group (IMWG) Mass Spectrometry Committee reviewed the literature in order to summarize current data and to make recommendations regarding the role of mass spectrometric methods in diagnosing and monitoring patients with myeloma and related disorders. Current literature demonstrates that immune-enrichment of immunoglobulins coupled to intact light chain MALDI-TOF MS has clinical characteristics equivalent in performance to IFE with added benefits of detecting additional risk factors for PCDs, differentiating Mprotein from therapeutic antibodies, and is a suitable replacement for IFE for diagnosing and monitoring multiple myeloma and related PCDs. In this paper we discuss the IMWG recommendations for the use of MS in PCDs.en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.titleExercise training and high-sensitivity cardiac troponin T in patients with heart failure with reduced ejection fractionen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.source.journalESC Heart Failureen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal